KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Globus Medical (GMED) Change in Accured Expenses (2016 - 2025)

Globus Medical (GMED) has disclosed Change in Accured Expenses for 15 consecutive years, with $8.8 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Change in Accured Expenses rose 89.36% year-over-year to $8.8 million, compared with a TTM value of $34.2 million through Dec 2025, up 581.21%, and an annual FY2025 reading of $34.2 million, up 581.21% over the prior year.
  • Change in Accured Expenses was $8.8 million for Q4 2025 at Globus Medical, down from $39.3 million in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $39.3 million in Q3 2025 and bottomed at -$33.9 million in Q1 2024.
  • Average Change in Accured Expenses over 5 years is $4.0 million, with a median of $6.5 million recorded in 2022.
  • Peak annual rise in Change in Accured Expenses hit 234.24% in 2024, while the deepest fall reached 239.86% in 2024.
  • Year by year, Change in Accured Expenses stood at $10.4 million in 2021, then crashed by 57.42% to $4.4 million in 2022, then plummeted by 177.98% to -$3.5 million in 2023, then surged by 234.24% to $4.6 million in 2024, then soared by 89.36% to $8.8 million in 2025.
  • Business Quant data shows Change in Accured Expenses for GMED at $8.8 million in Q4 2025, $39.3 million in Q3 2025, and $14.8 million in Q2 2025.